NEO SHAREHOLDER ALERT: Jakubowitz Law Reminds NeoGenomics Shareholders of a Lead Plaintiff Deadline of February 6, 2023

NEW YORK, Jan. 27, 2023

To receive updates on the lawsuit, fill out the form:
https://claimyourloss.com/securities/neogenomics-inc-loss-submission-form/?id=35960&from=4

The lawsuit seeks to recover losses for shareholders who purchased NeoGenomics between February 27, 2020 and April 26, 2022.

Shareholders interested in acting as a lead plaintiff representing the class of wronged shareholders have until February 6, 2023 to petition the court. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

According to a filed complaint, NeoGenomics, Inc. issued materially false and/or misleading statements and/or failed to disclose that: (1) defendants represented to investors that it had a "comprehensive menu" of cancer tests with "every kind of testing modality that you can use for cancer, including some of the fast-growing new ones, like next-generation sequencing," which positioned the Company as a "one-stop-shop" for pathologists and gave NeoGenomics "a competitive advantage" as a "go-to reference lab with a comprehensive menu for just about any kind of tests that you want to have done in cancer"; and (2) defendants represented that NeoGenomics could "leverage" the supposedly "fixed cost" structure of its business to improve profitability as revenue increased and touted the Company's "robust Compliance Program . . . to ensure compliance with the myriad of . . . laws, regulations and governmental guidance applicable to our business."

Jakubowitz Law is vigorous in pursuit of justice for shareholders who have been the victim of securities fraud. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
JAKUBOWITZ LAW
1140 Avenue of the Americas
9th Floor
New York, New York 10036
T: (212) 867-4490
F: (212) 537-5887